L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial

L-arginine supplementation and risk factors of... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/3-306" }, "headline": "L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind...", "datePublished": "2014-12-12T17:14:14", "dateModified": "2017-06-22T10:00:56", "author": [ { "@type": "Person", "name": "Naseh Pahlavani" }, { "@type": "Person", "name": "Mostafa Jafari" }, { "@type": "Person", "name": "Omid Sadeghi" }, { "@type": "Person", "name": "Masoud Rezaei" }, { "@type": "Person", "name": "Hamid Rasad" }, { "@type": "Person", "name": "Hossein Ali Rahdar" }, { "@type": "Person", "name": "Mohammad Hasan Entezari" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": "Context: The effect of L-arginine on risk factors of cardiovascular diseases (CVD) has mostly focused on western countries. Since cardiovascular diseases is the second cause of death in Iran and, as far as we are aware, there have been no studies about the effect of L-arginine on CVD risk factors, the aim of this trial was to assess the effects of L-arginine supplementation on CVD risk factors in healthy men. Objective: The purpose of this study was to evaluate the effect of low-dose L-arginine supplementation on CVD risk factors (lipid profile, blood sugar and blood pressure) in Iranian healthy men. Design, setting, participants: We conducted a double-blind randomized controlled trial in 56 patients selected from sport clubs at the Isfahan University of Medical Science between November 2013 and December 2013. Interventions: Healthy men received L-arginine supplementation (2000 mg daily) in the intervention group or placebo (2000 mg maltodextrin daily) in the control group for 45 days. Main outcome measure: The primary outcome measures were we measured the levels of fasting blood sugar, blood pressure and lipid profile including triglyceride (TG), cholesterol, LDL and HDL in healthy subjects. It was hypothesized that these measures would be significantly improved in those receiving L–arginine supplementation. at the beginning and end of the study. Results: In this trial, we had complete data for 52 healthy participants with mean age of 20.85±4.29 years. At the end of study, fasting blood sugar (P=0.001) and lipid profile (triglycerideTG (P<0.001), cholesterol (P<0.001), LDL (P=0.04), HDL (P=0.015)) decreased in the L-arginine group but we found no significant change in the placebo group. In addition, the reduction of fasting blood sugar and lipid profile in L-arginine was significant compared with placebo group. No significant changes were found about systolic (P=0.81) and diastolic blood pressure either in L-arginine or placebo group. (P=0.532). Conclusion: The use of L-arginine significantly improved outcomes compared to placebo." } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/3-306/v2", "name": "L-arginine supplementation and risk factors of cardiovascular diseases..." } } ] } Home Browse L-arginine supplementation and risk factors of cardiovascular diseases... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Pahlavani N, Jafari M, Sadeghi O et al. L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] . F1000Research 2017, 3 :306 ( https://doi.org/10.12688/f1000research.5877.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Research Article Clinical trial Revised L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] Naseh Pahlavani 1,2 , Mostafa Jafari 3 , Omid Sadeghi 4 , [...] Masoud Rezaei 5 , Hamid Rasad 2 , Hossein Ali Rahdar https://orcid.org/0000-0003-1583-9936 6 , Mohammad Hasan Entezari 2 Naseh Pahlavani 1,2 , Mostafa Jafari 3 , [...] Omid Sadeghi 4 , Masoud Rezaei 5 , Hamid Rasad 2 , Hossein Ali Rahdar https://orcid.org/0000-0003-1583-9936 6 , Mohammad Hasan Entezari 2 PUBLISHED 22 Jun 2017 Author details Author details 1 Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 2 Food Security Research Center and Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran 3 Student Research Committee, Arak University of Medical Science, Arak, Iran 4 Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran 5 Faculty of Nursing and Midwifery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 6 Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran OPEN PEER REVIEW DETAILS REVIEWER STATUS This article is included in the Sports cardiology collection. This article is included in the All trials matter collection. Abstract Context: The effect of L-arginine on risk factors of cardiovascular diseases (CVD) has mostly focused on western countries. Since cardiovascular diseases is the second cause of death in Iran and, as far as we are aware, there have been no studies about the effect of L-arginine on CVD risk factors, the aim of this trial was to assess the effects of L-arginine supplementation on CVD risk factors in healthy men. Objective: The purpose of this study was to evaluate the effect of low-dose L-arginine supplementation on CVD risk factors (lipid profile, blood sugar and blood pressure) in Iranian healthy men. Design, setting, participants: We conducted a double-blind randomized controlled trial in 56 patients selected from sport clubs at the Isfahan University of Medical Science between November 2013 and December 2013. Interventions: Healthy men received L-arginine supplementation (2000 mg daily) in the intervention group or placebo (2000 mg maltodextrin daily) in the control group for 45 days. Main outcome measure: The primary outcome measures were we measured the levels of fasting blood sugar, blood pressure and lipid profile including triglyceride (TG), cholesterol, LDL and HDL in healthy subjects. It was hypothesized that these measures would be significantly improved in those receiving L–arginine supplementation. at the beginning and end of the study. Results: In this trial, we had complete data for 52 healthy participants with mean age of 20.85±4.29 years. At the end of study, fasting blood sugar (P=0.001) and lipid profile (triglycerideTG (P<0.001), cholesterol (P<0.001), LDL (P=0.04), HDL (P=0.015)) decreased in the L-arginine group but we found no significant change in the placebo group. In addition, the reduction of fasting blood sugar and lipid profile in L-arginine was significant compared with placebo group. No significant changes were found about systolic (P=0.81) and diastolic blood pressure either in L-arginine or placebo group. (P=0.532). Conclusion : The use of L-arginine significantly improved outcomes compared to placebo. READ ALL READ LESS Corresponding Author(s) Mohammad Hasan Entezari ( [email protected] ) Close Corresponding author: Mohammad Hasan Entezari Competing interests: No competing interests were disclosed. Grant information: Funding for this study was provided by Department of Clinical Nutrition, School of Nutrition and Food Sciences, Isfahan, Iran, grant number: 392435. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2017 Pahlavani N et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication). How to cite: Pahlavani N, Jafari M, Sadeghi O et al. L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] . F1000Research 2017, 3 :306 ( https://doi.org/10.12688/f1000research.5877.2 ) First published: 12 Dec 2014, 3 :306 ( https://doi.org/10.12688/f1000research.5877.1 ) Latest published: 22 Jun 2017, 3 :306 ( https://doi.org/10.12688/f1000research.5877.2 ) Revised Amendments from Version 1 In response to the Referees’ reports, the following changes have been made in our Version 2: •In the Introduction, we’ve expanded on what basis the arginine dosage was selected, citing Elam et al., 1989 •In the Results, we’ve clarified why the statistical correlations between the arginine and the age, BMI and Physical activity was not addressed in our version 1 •We’ve presented the Conclusion as a separate section In response to the Referees’ reports, the following changes have been made in our Version 2: •In the Introduction, we’ve expanded on what basis the arginine dosage was selected, citing Elam et al., 1989 •In the Results, we’ve clarified why the statistical correlations between the arginine and the age, BMI and Physical activity was not addressed in our version 1 •We’ve presented the Conclusion as a separate section See the authors' detailed response to the review by Majid Ghayour-Mobarhan READ REVIEWER RESPONSES Introduction High blood pressure is now considered one of the main challenges facing human health and is one of the most important risk factors for cardiovascular disease 1 . It is predicted that the incidence of cardiovascular disease and hypertension will reach in about 30% of the world population by the year 2025. Iran is the fifth country in the world in terms of having high blood pressure related diseases. Approximately 6.6 million with an age range of 25–64 years have high blood pressure and an estimated 12 million people in the same age range are at increased risk of hypertension and cardiovascular disease 2 , 3 . One of the major mechanisms of cardiovascular disease is endothelial dysfunction. Dysfunction, which can increase the permeability of the plasma components, especially low-density lipoproteins (LDL) and deposition in the sub endothelial space, can be considered one of the earliest events that occur in atherosclerosis 4 , 5 . With the high prevalence of hypertension and cardiovascular diseases and complications, and high costs that they impose on society, presentation of new strategies for prevention and control of these diseases, as well as finding efficient and effective complementary therapies with few instances of complications is very important 6 . L-arginine is a semi-essential amino acid that is used by all cells 7 . This amino acid, on average, constitutes 7–5% of the total amino acids in the normal human diet and is absorbed in the jejunum and ileum of the small intestine. L-arginine is used by the body in protein synthesis, urea cycle, tissue repairing and immune cell function 8 , 9 . Arginine is converted to nitric oxide and citrulline, which acts as a vasodilator. There are three isoforms of nitric oxide synthase (NOS), these isoforms need oxygen, arginine and Tetrahydrobiopterin 4 (BH4) and NADPH (nicotine amide adenine di nucleotides phosphate) for the synthesis of nitric oxide 10 . In a trial conducted on Zucker rats, L-arginine reduced adipose tissue 11 . Recently, arginine-rich foods were shown to be inversely associated with endothelial dysfunction in hypercholesterolemia patients 12 . It has also been shown that long-term administration of L-arginine reduces cardiovascular complications 13 . It is still not entirely clear that a low dose of L-arginine has a positive effect. Nitric oxide has an important function in fat metabolism 14 . Physiological levels of nitric oxide (25 to 35 µmol) increased oxidation of glucose and fat and prevented the synthesis of glucose and triglycerides 15 . Several amino acids, particularly arginine, glutamine, leucine and phenylalanine directly stimulate the production of insulin from pancreatic beta cells 16 . Other possible actions associated with L-arginine include lowering blood pressure and homocysteine levels, increasing lean body mass and decreasing fat mass and adiponectin and endothelin 17 . In one study conducted by Sato et al. , infusion of L-arginine reduced blood pressure in patients with essential hypertension but was not effective in patients with a history of dangerously high blood pressure 18 . In a study conducted on healthy volunteers, supplementing with L-arginine for 3 days in a week improved glucose metabolism 19 , 20 . In a study, Lucotti et al. demonstrated that prolonged treatment with L-arginine in patients with type 2 diabetes caused a significant decrease in blood sugar 21 . In general, a number of studies on the beneficial effects of L-arginine have been shown to reduce blood pressure 22 . But in some other studies, L-arginine had no effect on blood pressure 23 , 24 . In previous studies, the effects of long-term, low L-arginine intake have not been examined. To best of our knowledge, no study has evaluated the effects of 2g of L-arginine per day on cardiovascular risk factors. Based on the L-arginine dosage used in Elam et al. 25 , and based on their conclusion that increasing the duration of L-arginine supplementation can be more effective than increasing the dosage of L-arginine, this clinical trial aimed to evaluate the effects of 45 days L-arginine supplementation (2g per day) on lipid profiles, fasting blood glucose and blood pressure in male athletes. In the present study, we hypothesized that 2g per day L-arginine supplementation during 45 days provides better outcomes on cardiovascular risk factors than other dosages used in previous studies. Therefore, in this study, we examined the effect of L-arginine supplementation on lipid profile, blood pressure and fasting blood sugar (glucose; FBS) in healthy men. Material and methods Study design This double-blind randomized clinical trial (IRCT2013060411763N9) was conducted on 56 healthy male sports club members of Isfahan University of Medical Sciences, Isfahan, Iran, from November 2013 to December, 2013. Inclusion and exclusion criteria Male participants, with no history of smoking or alcohol consumption during the past year, not taking nutritional sport supplements during the last 2 months, no acute or chronic illness (including mental disorders, untreated hypothyroidism, heart and kidney disease, hepatitis, infectious and inflammatory diseases) and 18 to 35 years of age were included in this trial. Participants with any of the aforementioned diseases were excluded from this study. Sample size Participants were invited to participate in the study by advertising at sports clubs at Isfahan University of Medical Sciences, Isfahan, Iran. A total of 70 men participated in the study, 56 subjects of which fitted the inclusion criteria. The required sample size was determined by following formula, considering a study power of 80%, a type I error of 5% (α = 0.05) and type II error of 20% (β = 0.20). N = 2 ( Z 1 + Z 2 ) σ 2 d 2 Data collection We held five meeting with participants. In the first meeting, we obtained basic information using a general questionnaire. For dietary assessment, three-day dietary records of subjects (sessions 2, 3 and 4) were completed and the nutrient content of foods were determined by the Nutritionist 4 software (version 7.0; N-Squared Computing, Salem, OR), which was designed for evaluation of Iranian foods. Participants were instructed to record, as accurately as possible, everything they consumed during the day including supplements and between-meal and late-evening snacks. Physical activity level was assessed at baseline (session 1) and at the end of study (session 5) by using the IPAQ questionnaire, which is both a reliable (Tang K Hong et al. ) and valid (Coral et al. ) measure 26 , 27 . Weight was measured without shoes while the participants wore underwear and were recorded to the nearest 0.5 kg. BMI was calculated as weight in kilograms divided by height in meters squared. Height was measured without shoes while the shoulders were in a normal position. Fasting blood samples were collected at day 0 (session 1) and day 45 (session 5) of this trial. The blood samples were separated at 4°C for 10 min centrifugation at 4000 rpm and the serum was frozen at -80°C until analysis. FBS levels and lipid profile including total cholesterol (TC), triglyceride (TG), LDL and HDL, were measured using Auto Analyser Biosystems A25 (BioSystems S.A., Barcelona, Spain). Blood pressure was measured three times in every session after a 15 minute rest sitting down by mercury sphygmomanometer and the average blood pressure obtained was recorded at each stage. Intervention After obtaining informed consent and with the approval of the ethics committee of Isfahan University of Medical Sciences, 56 healthy men participated in this study and were randomly assigned to consume L-arginine supplement ( n = 28) or placebo ( n = 28) for 45 days using envelopes containing numbers from a table of random numbers. Pure L-arginine supplements and placebo (maltodextrin) were purchased from a pharmaceutical company (Karen Pharmaceutical Co, Yazd-Iran). Participants were instructed to take one table per day (2000 mg of L-arginine in the L-arginine group, 2000 mg of maltodextrin in the placebo group). When the participants were given packets of L-arginine or placebo they were asked not to change the lifestyle, physical activity and diet during the study. For blinding, L-arginine and placebo packets were coded by someone outside the research team and the research team was unaware of the type of supplement. The L-arginine and placebo packets were delivered to participants at session 1 and 3. They were asked to bring back the empty packets at session 3 and the final session. The statistician was also not aware of the type of intervention. At the end of the project the final report determined the type of intervention. This trial was approved by the Isfahan University of Medical Sciences (with the number 392435) and was registered in clinical trials center’s website address ( www.irct.ir ) (code: IRCT2013121515807N1). Adverse effects The incidence of adverse events was evaluated by recording all observed or volunteered adverse events. For this purpose, any study related adverse events during intervention were monitored by daily evaluation. For participants who withdrew or subjects lost to follow-up, adverse events were acquired by telephone. Statistical analysis All statistical analyses were done by means of SPSS software version 18 (SPSS, Inc. Chicago, IL, USA). We applied Kolmogrov–Smirnov test to ensure the normal distribution of variables. To determine the differences in general characteristics and dietary intakes between L-arginine and placebo groups, we used an independent-samples t-test. We used paired-samples t-tests to determine the effects of L-arginine and placebo on FBS, lipid profile and blood pressure. P-value < 0.05 was considered as the level of significance. Results Fifty-six of the subjects fulfilled the inclusion criteria and participated in the study, but four dropped out the study with these reasons: two due to dermatitis and one for digestive problems in the intervention group and one in the placebo group because of personal problems. Therefore, 52 participants [L-arginine (n = 25) and placebo (n = 27)] completed the trial ( Figure 1 ). Final statistical analyses were performed on the 52 participants. The rate of compliance in our study was high, such that approximately 100% of capsules were taken throughout the study in both groups. General characteristics of participants who received either L-arginine supplements or placebo are illustrated in Table 1 . No significant differences were found in weight, BMI, physical activity, energy or protein intake between both groups ( Table 1 ). Because L-arginine levels in serum were not measured during the study, there was no possibility of getting correlation between arginine and age, BMI and PA. Figure 1. Schematic diagram of the study; Individuals in the L-arginine group received capsule containing 2000 mg of L-arginine per day during the study; those in the placebo group received 2000 mg placebo capsule at the same times. Table 1. General baseline characteristics of athletic men who received either L-arginine supplements or placebo 1 . L-arginine group 3 (n = 25) Placebo group 2 (n = 27) P value 4 Age (y) 21.32±4.59 20.40±4.04 0.44 BMI (kg/m 2 ) 23.34±4.02 24.01±4.53 0.574 Height (cm) 175.48±6.40 176±7.06 0.783 Weight (kg) 73.82±14.02 72.90±16.32 0.830 Physical activity (MET-minutes/week) 3941.44±987.70 3810.09±1199.69 0.670 Energy Intake (Kcal) 2251.46±362.01 2232.65±341.48 0.848 Protein Intake (g/d) 83.04±14.13 80.66±7.52 0.447 1 All values are means ±SDs 2 Received placebo 2000 mg per day during the study 3 Received L-arginine supplement 2000 mg per day during study 4 Obtained from independent-samples t test The differences between the two groups in dietary intake during the trial are presented in Table 2 . Dietary intake of energy, protein, carbohydrate, fat and arginine during study were not different between L-arginine and placebo groups. Table 2. Dietary assessment in L-arginine and placebo groups. Variables L-arginine group n = 25 Placebo group n = 27 P-value † Energy (Kcal) 2251.46±362.01 2232.65±341.48 0.848 Carbohydrate (g) 327.52±40.86 317.47±27.78 0.310 Protein (g) 83.04±14.13 80.66±7.52 0.459 Fat (g) 66.44±12.43 69.24±8.93 0.351 Arginine (mg) 388.73±464.33 437.97±458.29 0.702 Data is presented as mean and standard deviation †Obtained from independent sample t test Table 3. Fasting blood sugar, lipid profile, systolic and diastolic blood pressure in L-arginine and placebo groups. Variables L-arginine group (n = 25) 1 Placebo group (n = 27) 2 P-value 4 Baseline After Change P-value Baseline After Change P-value 3 FBS (mg/dl) 99.28 ± 7.78 96.92 ± 7.86 -2.36 ± 2.04 0.001> 99.55 ± 5.65 99.89 ± 5.76 0.33 ± 1.39 0.223 0.001 TG (mg/dl) 74.48 ± 15.91 71 ± 15.67 -2.81 ± 3.01 0.001> 74.85 ± 14.39 74.92 ± 14.61 0.7 ± 2.11 0.857 0.001> LDL (mg/dl) 100.08 ± 10.46 98.81 ± 10.91 -1.28 ± 1.65 0.01 98.55 ± 10.53 98.63 ± 10.78 0.07 ± 1.57 0.808 0.04 HDL (mg/dl) 59.31 ± 7.93 61.06 ± 7.16 1.04 ± 1.46 0.001> 60.11 ± 7.09 60.21 ± 6.85 0.08 ± 1.14 0.702 0.015 Cholesterol (mg/dl) 156.32 ± 17.53 153.96 ± 17.09 -2.36 ± 2.22 0.001> 158.92 ± 11.88 159.03 ± 11.74 0.11 ± 1.95 0.769 0.001> SBP (mmHg) 115.41 ± 6.11 114.01 ± 4.78 -1.41 ± 3.07 0.032 107.22 ± 5.43 117.22 ± 4.66 0 ± 3.11 0.001 0.81 DBP (mmHg) 74.4 ± 6.56 73.01 ± 4.33 -1.41 ± 3.68 0.07 75.92 ± 4.16 75.18 ± 4.04 -0.74 ± 3.85 0.327 0.532 Data is presented as mean and standard deviation Abbreviation: fasting blood sugar, triglyceride, low density lipoprotein, high density lipoprotein, systolic blood pressure, diastolic blood pressure 1 Received L-arginine 2000 mg per day during study 2 Received placebo 2000 mg per day during the study 3 Obtained from paired-samples t test 4 Obtained from independent-samples t test Baseline and after intervention values of FBS, blood pressure and lipid profile are presented in ( Table 3 ). In this study, supplementation of 2000 mg L-arginine per day compared with placebo (2000 mg maltodextrin) for 45 days were given to participants. Levels of FBS, triglycerides, total cholesterol, LDL-c and HDL-c in L-arginine supplemented group compared with the placebo group showed statistically significant differences (P0.05) ( Table 3 ). Discussion In this study, the effect of L-arginine supplementation on blood glucose, blood pressure and lipid profile in healthy male subjects between 18 and 35 years were examined. In the intervention group of subjects receiving 2000 mg daily of L-arginine pills for 45 days and the control group participants 2000 mg daily placebo pills (maltodextrin) consumed. The results showed that L-arginine supplementation significantly decreased the levels of FBS, triglycerides, LDL and cholesterol and a significant increase in HDL levels compared to the control group (P0.05) ( Table 3 ). In some studies, healthy individuals exhibited improved glucose metabolism after three to seven days of L-arginine supplementation 19 , 28 , a result that is in line with our study. Lucotti et al. demonstrated that L-arginine supplementation reduces blood sugar in patients with diabetes, which also parallels with our study, although our study was conducted on healthy people 21 . There is evidence that long-term L-arginine intake can increase insulin sensitivity and improve the glycemic indices 29 . It seems that an acute dose of L-arginine affects the levels of nitric oxide. In a study conducted by Natarajan et al. , supplementation with L-arginine improves glycemic sensitivity in patients with diabetes 30 . In another study Mohamadian and colleagues demonstrated that nitric oxide precursors can improve blood glucose and glycosylated hemoglobin levels in Wistar rats with diabetes through antioxidant activity 31 . In a study conducted on people with type 2 diabetes, L-arginine supplementation reduced systolic and diastolic blood pressure, results that are inconsistent with our results 32 . However, a study by Lerman et al. , found that L-arginine supplementation over 6 months had no significant effect on systolic and diastolic blood pressure in humans, which is in line with our study 24 . Lekakis and colleagues found similar results where a daily 6 g oral dose of L-arginine did not have a significant effect on blood pressure of patients with essential hypertension 23 . Siani et al. lowering blood sugar, lowering blood pressure, increasing HDL, cholesterol and triglycerides and decreased following administration of L-arginine supplementation reported, that the results of this study agree with our study 19 . In a study conducted in 2008 by Boger et al. , supplementation with L-arginine improved the function of the cardiovascular system in patients on hemodialysis 32 . Several studies that were carried out on humans and male C57BL/6 mice have shown that L-arginine supplementation may be considered a new treatment for metabolic disorders and also has an effect of lowering blood pressure, adipose tissue and weight and improves insulin sensitivity 33 – 35 . In a study conducted by Martina et al. L-arginine supplementation of 2.1 g per day in combination with N-acetylcysteine at a dose of 2.1 g per day for 6 months has been shown to improve endothelial function 36 . In one study, M.A. Nascimento et al. showed that L-arginine supplementation in overweight men for 7 days reduced LDL and increased HDL, results that agree with the results of our study. However, unlike our findings, they did not see any effect on the levels of triglycerides and total cholesterol. These differing results may be due to the short duration of their study, as well as the high BMI and average age of their participants (46 ± 5) 37 . Mechanisms activated by L-arginine supplementation are still not fully understood. L-arginine can affect the molecular and cellular levels via complex mechanisms. Studies on multiple animal models and in a limited number of human subjects have shown that L-arginine can stimulate the development of brown adipose tissue mitochondria and induce the regulation of gene expression 38 . Another study reported that L-arginine supplementation decreased blood pressure and total homocysteine levels 39 . Indeed, nitric oxide is produced from arginine as an endothelium relaxation factor, which activates guanylyl cyclase. Guanylyl cyclase converted guanylyl triphosphate to cyclic guanylyl monophosphate which relaxes the smooth muscles that can cause a decrease in blood pressure 40 , 41 . Although the results of many studies are in line with our study, more are needed to determine the effects of differing L-arginine doses on CVD risk factors. Some limitations of this study should be considered. First, we could not examine the effects of L-arginine supplementation on inflammation factors including tumor necrosis factor alpha (TNF-α) C-reactive protein (CRP) and interleukin-6 as CVD risk factors. Second, this study was conducted on males and it is not clear the effects of L-arginine supplementation on CVD risk factors on females. Third, in this study, we just enrolled healthy subjects and we did not examine the effects of L-arginine on patients with CVD. Conclusion The intake of 2 g of L-arginine per day, for 45 days, could improve the lipid profile and FBS in male athletes, but has no effect on systolic and diastolic blood pressure. Further studies based on determination of L-arginine dose and with a larger sample size are needed to shed light on our findings. Data availability Figshare: http://dx.doi.org/10.6084/m9.figshare.1265047 41 Author contributions We strongly encourage authors to make these statements, specifying the ways in which the authors contributed to the paper. All authors contributed equally to this work. N.P, M.J, M.R and H.R performed conception, design, data collection and clinical studies. H.A.R did the literature search. O.S conducted all statistical analysis. N.P, O.S and M.H.E performed the manuscript preparation, editing and review. Funding and overall responsibility was assumed by M.H.E. Competing interests No competing interests were disclosed. Grant information Funding for this study was provided by Department of Clinical Nutrition, School of Nutrition and Food Sciences, Isfahan, Iran, grant number: 392435. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Acknowledgements This study was supported by Department of clinical Nutrition, School of Nutrition and Food Sciences, Isfahan, Iran. The authors thank the athletes who participated in the research project. Faculty Opinions recommended References 1. Burke BE, Neuenschwander R, Olson RD: Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J. 2001; 94 (11): 1112–7. PubMed Abstract 2. Kapil V, Milsom AB, Okorie M, et al. : Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO. Hypertension. 2010; 56 (2): 274–81. PubMed Abstract | Publisher Full Text 3. Esteghamati A, Abbasi M, Alikhani S, et al. : Prevalence, awareness, treatment, and risk factors associated with hypertension in the Iranian population: the national survey of risk factors for noncommunicable diseases of Iran. Am J Hypertens. 2008; 21 (6): 620–6. PubMed Abstract | Publisher Full Text 4. Marx N, Grant PJ: Endothelial dysfunction and cardiovascular disease--the lull before the storm. Diab Vasc Dis Res. 2007; 4 (2): 82–3. PubMed Abstract | Publisher Full Text 5. Hadi HA, Carr CS, Al Suwaidi J: Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005; 1 (3): 183–98. PubMed Abstract | Free Full Text 6. Rosenfeldt FL, Haas SJ, Krum H, et al. : Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007; 21 (4): 297–306. PubMed Abstract | Publisher Full Text 7. Wu G, Morris SM Jr: Arginine metabolism: nitric oxide and beyond. Biochem J. 1998; 336 (Pt 1): 1–17. PubMed Abstract | Free Full Text 8. White MF: The transport of cationic amino acids across the plasma membrane of mammalian cells. Biochim Biophys Acta. 1985; 822 (3–4): 355–74. PubMed Abstract | Publisher Full Text 9. Hendler SS, Rorvik D: PDR for nutritional supplements. 1st ed. Montvale, NJ; PDR Thompson. 2001. Reference Source 10. Wu G, Bazer FW, Davis TA, et al. : Arginine metabolism and nutrition in growth, health and disease. Amino Acids. 2009; 37 (1): 153–68. PubMed Abstract | Publisher Full Text | Free Full Text 11. Fu WJ, Haynes TE, Kohli R, et al. : Dietary L-arginine supplementation reduces fat mass in Zucker diabetic fatty rats. J Nutr. 2005; 135 (4): 714–21. PubMed Abstract 12. Maxwell AJ, Anderson B, Zapien MP, et al. : Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity. Cardiovasc Drugs Ther. 2000; 14 (3): 309–16. PubMed Abstract | Publisher Full Text 13. Sozykin AV, Noeva EA, Balakhonova TV, et al. : [Effect of L-arginine on platelet aggregation, endothelial function and exercise tolerance in patients with stable angina pectoris]. Ter Arkh. 2000; 72 (8): 24–27. PubMed Abstract 14. Garcia-Villafranca J, Guillen A, Castro J: Involvement of nitric oxide/cyclic GMP signaling pathway in the regulation of fatty acid metabolism in rat hepatocytes. Biochem Pharmacol. 2003; 65 (5): 807–12. PubMed Abstract | Publisher Full Text 15. Jobgen WS, Fried SK, Fu WJ, et al. : Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem. 2006; 17 (9): 571–88. PubMed Abstract 16. Menge BA, Schrader H, Ritter PR, et al. : Selective amino acid deficiency in patients with impaired glucose tolerance and type 2 diabetes. Regul Pept. 2010; 160 (1–3): 75–80. PubMed Abstract | Publisher Full Text 17. Cassone Faldetta M, Laurenti O, Desideri G, et al. : L-arginine infusion decreases plasma total homocysteine concentrations through increased nitric oxide production and decreased oxidative status in Type II diabetic patients. Diabetologia. 2002; 45 (8): 1120–7. PubMed Abstract | Publisher Full Text 18. Sato K, Kinoshita M, Kojima M, et al. : Failure of L-arginine to induce hypotension in patients with a history of accelerated-malignant hypertension. J Hum Hypertens. 2000; 14 (8): 485–8. PubMed Abstract | Publisher Full Text 19. Siani A, Pagano E, Iacone R, et al. : Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. Am J Hypertens. 2000; 13 (5 Pt 1): 547–51. PubMed Abstract | Publisher Full Text 20. Apostol AT, Tayek JA: A decrease in glucose production is associated with an increase in plasma citrulline response to oral arginine in normal volunteers. Metabolism. 2003; 52 (11): 1512–6. PubMed Abstract | Publisher Full Text 21. Lucotti P, Setola E, Monti LD, et al. : Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2006; 291 (5): E906–12. PubMed Abstract | Publisher Full Text 22. Rector TS, Bank AJ, Mullen KA, et al. : Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation. 1996; 93 (12): 2135–41. PubMed Abstract | Publisher Full Text 23. Lekakis JP, Papathanassiou S, Papaioannou TG, et al. : Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol. 2002; 86 (2–3): 317–23. PubMed Abstract | Publisher Full Text 24. Lerman A, Burnett JC Jr, Higano ST, et al. : Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998; 97 (21): 2123–8. PubMed Abstract | Publisher Full Text 25. Elam RP, Hardin DH, Sutton RA: Effects of arginine and ornithine on strength, lean body mass and urinary hydroxyproline in adult males. J Sports Med Phys Fitness. 1989; 29 (1): 52–56. PubMed Abstract 26. Craig CL, Marshall AL, Sjöström M, et al. : International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003; 35 (8): 1381–95. PubMed Abstract 27. Hong TK, Trang NH, van der Ploeg HP, et al. : Validity and reliability of a physical activity questionnaire for Vietnamese adolescents. Int J Behav Nutr Phys Act. 2012; 9 : 93. PubMed Abstract | Publisher Full Text | Free Full Text 28. Gannon MC, Nuttall JA, Nuttall FQ: Oral arginine does not stimulate an increase in insulin concentration but delays glucose disposal. Am J Clin Nutr. 2002; 76 (5): 1016–22. PubMed Abstract 29. Wascher TC, Graier WF, Dittrich P, et al. : Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity. Eur J Clin Invest. 1997; 27 (8): 690–5. PubMed Abstract 30. Natarajan Sulochana K, Lakshmi S, Punitham R, et al. : Effect of oral supplementation of free amino acids in type 2 diabetic patients-- a pilot clinical trial. Med Sci Monit. 2002; 8 (3): CR131–7. PubMed Abstract 31. Mohamadin AM, Hammad LN, El-Bab MF, et al. : Can nitric oxide-generating compounds improve the oxidative stress response in experimentally diabetic rats? Clin Exp Pharmacol Physiol. 2007; 34 (7): 586–93. PubMed Abstract | Publisher Full Text 32. Boger RH: L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous? Curr Opin Clin Nutr Metab Care. 2008; 11 (1): 55–61. PubMed Abstract | Publisher Full Text 33. McKnight JR, Satterfield MC, Jobgen WS, et al. : Beneficial effects of L-arginine on reducing obesity: potential mechanisms and important implications for human health. Amino Acids. 2010; 39 (2): 349–57. PubMed Abstract | Publisher Full Text 34. Clemmensen C, Madsen AN, Smajilovic S, et al. : L-Arginine improves multiple physiological parameters in mice exposed to diet-induced metabolic disturbances. Amino Acids. 2012; 43 (3): 1265–75. PubMed Abstract | Publisher Full Text 35. Martina V, Masha A, Gigliardi VR, et al. : Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care. 2008; 31 (5): 940–4. PubMed Abstract | Publisher Full Text 36. Nascimento MA, Higa EMS, de Mello MT, et al. : “Effects of short-term L-arginine supplementation on lipid profile and inflammatory proteins after acute resistance exercise in overweight men”. e-SPEN J. 2014; 9 (3): e141–e145. Publisher Full Text 37. McKnight JR, Satterfield MC, Jobgen WS, et al. : Beneficial effects of L-arginine on reducing obesity: potential mechanisms and important implications for human health. Amino Acids. 2010; 39 (2): 349–57. PubMed Abstract | Publisher Full Text 38. Cassone Faldetta M, Laurenti O, Desideri G, et al. : L-arginine infusion decreases plasma total homocysteine concentrations through increased nitric oxide production and decreased oxidative status in Type II diabetic patients. Diabetologia. 2002; 45 (8): 1120–7. PubMed Abstract | Publisher Full Text 39. Gruetter CA, Barry BK, McNamara DB, et al. : Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res. 1979; 5 (3): 211–224. PubMed Abstract 40. Huynh NT, Tayek JA: Oral arginine reduces systemic blood pressure in type 2 diabetes: its potential role in nitric oxide generation. J Am Coll Nutr. 2002; 21 (5): 422–7. PubMed Abstract | Publisher Full Text 41. Pahlavani N, Entezari MH, Nasiri M, et al. : The effect of l-arginine supplementation on body composition and performance in male athletes: a double-blinded randomized clinical trial. Eur J Clin Nutr. 2017; 71 (4): 544–548. PubMed Abstract | Publisher Full Text Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 12 Dec 2014 ADD YOUR COMMENT Comment Author details Author details 1 Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 2 Food Security Research Center and Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran 3 Student Research Committee, Arak University of Medical Science, Arak, Iran 4 Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran 5 Faculty of Nursing and Midwifery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 6 Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Competing interests No competing interests were disclosed. Grant information Funding for this study was provided by Department of Clinical Nutrition, School of Nutrition and Food Sciences, Isfahan, Iran, grant number: 392435. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article Versions (2) version 2 Revised Published: 22 Jun 2017, 3:306 https://doi.org/10.12688/f1000research.5877.2 version 1 Published: 12 Dec 2014, 3:306 https://doi.org/10.12688/f1000research.5877.1 Copyright © 2017 Pahlavani N et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication). Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Pahlavani N, Jafari M, Sadeghi O et al. L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] . F1000Research 2017, 3 :306 ( https://doi.org/10.12688/f1000research.5877.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 2 VERSION 2 PUBLISHED 22 Jun 2017 Revised Views 0 Cite How to cite this report: Ghayour-Mobarhan M. Reviewer Report For: L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] . F1000Research 2017, 3 :306 ( https://doi.org/10.5256/f1000research.12610.r23982 ) The direct URL for this report is: https://f1000research.com/articles/3-306/v2#referee-response-23982 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 03 Jul 2017 Majid Ghayour-Mobarhan , Cardiovascular Research Center, Mashhad University of Medical Science, Mashhad, Iran Approved VIEWS 0 https://doi.org/10.5256/f1000research.12610.r23982 The authors have edited the ... Continue reading READ ALL The authors have edited the manuscript according to the referee comments. Competing Interests: No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Ghayour-Mobarhan M. Reviewer Report For: L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] . F1000Research 2017, 3 :306 ( https://doi.org/10.5256/f1000research.12610.r23982 ) The direct URL for this report is: https://f1000research.com/articles/3-306/v2#referee-response-23982 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Version 1 VERSION 1 PUBLISHED 12 Dec 2014 Views 0 Cite How to cite this report: Ghayour-Mobarhan M. Reviewer Report For: L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] . F1000Research 2017, 3 :306 ( https://doi.org/10.5256/f1000research.6279.r8320 ) The direct URL for this report is: https://f1000research.com/articles/3-306/v1#referee-response-8320 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 14 Apr 2015 Majid Ghayour-Mobarhan , Cardiovascular Research Center, Mashhad University of Medical Science, Mashhad, Iran Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.6279.r8320 The title and abstract are appropriate, as are the methods and analysis. The conclusions presented are justified based on the results, and the data provided is sufficient. Please make the following modifications in your article: The statistical correlations between the arginine and ... Continue reading READ ALL The title and abstract are appropriate, as are the methods and analysis. The conclusions presented are justified based on the results, and the data provided is sufficient. Please make the following modifications in your article: The statistical correlations between the arginine and the age, BMI and Physical activity should be assessed and reported. On what basis was the arginine dosage selected? The conclusion should be present in a separate section. Competing Interests: No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Ghayour-Mobarhan M. Reviewer Report For: L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] . F1000Research 2017, 3 :306 ( https://doi.org/10.5256/f1000research.6279.r8320 ) The direct URL for this report is: https://f1000research.com/articles/3-306/v1#referee-response-8320 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 22 Jun 2017 Mostafa Jafari , Student Research Committee, Arak University of Medical Science, Arak, Iran 22 Jun 2017 Author Response Dear Referee Your comments on my article with title (L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial) were modified and submitted ... Continue reading Dear Referee Your comments on my article with title (L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial) were modified and submitted in new version. but in one comment :(The statistical correlations between the arginine and the age, BMI and Physical activity should be assessed and reported) Because L-arginine levels in serum was not measured during the study, there was no possibility of getting correlation between arginine and age, BMI and PA Thanks Dear Referee Your comments on my article with title (L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial) were modified and submitted in new version. but in one comment :(The statistical correlations between the arginine and the age, BMI and Physical activity should be assessed and reported) Because L-arginine levels in serum was not measured during the study, there was no possibility of getting correlation between arginine and age, BMI and PA Thanks Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 22 Jun 2017 Mostafa Jafari , Student Research Committee, Arak University of Medical Science, Arak, Iran 22 Jun 2017 Author Response Dear Referee Your comments on my article with title (L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial) were modified and submitted ... Continue reading Dear Referee Your comments on my article with title (L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial) were modified and submitted in new version. but in one comment :(The statistical correlations between the arginine and the age, BMI and Physical activity should be assessed and reported) Because L-arginine levels in serum was not measured during the study, there was no possibility of getting correlation between arginine and age, BMI and PA Thanks Dear Referee Your comments on my article with title (L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial) were modified and submitted in new version. but in one comment :(The statistical correlations between the arginine and the age, BMI and Physical activity should be assessed and reported) Because L-arginine levels in serum was not measured during the study, there was no possibility of getting correlation between arginine and age, BMI and PA Thanks Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Leischik R. Reviewer Report For: L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] . F1000Research 2017, 3 :306 ( https://doi.org/10.5256/f1000research.6279.r7756 ) The direct URL for this report is: https://f1000research.com/articles/3-306/v1#referee-response-7756 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 03 Mar 2015 Roman Leischik , Department of Cardiology, Witten/Herdecke University, Hagen, Germany Approved VIEWS 0 https://doi.org/10.5256/f1000research.6279.r7756 The study is well conducted. The data support the conclusions. We don`t know anything about the long-term results. For this issue it is necessary to perform long-term studies. L-Arginine supplement was used in sport, but its positive effects on it ... Continue reading READ ALL The study is well conducted. The data support the conclusions. We don`t know anything about the long-term results. For this issue it is necessary to perform long-term studies. L-Arginine supplement was used in sport, but its positive effects on it are not sure 1 . Plasma nitrite levels were elevated compared to placebo during acute supplement in 5 km runners. We don`t know the long-term effects in patients with diabetes or patients with CAD over the years. But some cited studies in this well conducted study are promising. I think, because of the financial problems we don´t will have a well performed double blinded long-term study in the future. It is therefore quite beneficial to have a well conducted study, especially about possible adverse effects. It is interesting that lowering of blood pressure showed negative effects, but maybe the underlying mechanism in patients with metabolic syndrome might lead to other effects. If it is possible, it would be necessary to get a grant for a long-term study, because the adverse effects are low and possible positive effects might be significant. The problem is that physical activity and healthy life style in general is more important as all supplements. There is a great desire in patients for taking supplements or pills as a solution for their problems and diseases, because then there is no need for an individually effort of the patient itself. I think it is important to mention this. Further studies should be carried out comparing the effects of supplementation of L-Arginine and physical activity in patients. But we have to start somewhere with research and this study is one of the first well conducted and transparent studies. It would be nice if the author can discuss the problem physical activity 2 /life style 3 and supplements in the discussion section. Socioeconomic differences might play a greater role as supplement with L-Arginine 4 . References 1. Sandbakk SB, Sandbakk O, Peacock O, James P, et al.: Effects of acute supplementation of L-arginine and nitrate on endurance and sprint performance in elite athletes. Nitric Oxide . 2014. PubMed Abstract | Publisher Full Text | Reference Source 2. Fiuza-Luces C, Garatachea N, Berger NA, Lucia A: Exercise is the real polypill. Physiology (Bethesda) . 2013; 28 (5): 330-358 PubMed Abstract | Publisher Full Text | Reference Source 3. Edwardson CL, Gorely T, Davies MJ, Gray LJ, et al.: Association of sedentary behaviour with metabolic syndrome: a meta-analysis. PLoS One . 2012; 7 (4). PubMed Abstract | Free Full Text | Publisher Full Text | Reference Source 4. Lindstrom M, Hanson BS, Ostergren PO: Socioeconomic differences in leisure-time physical activity: the role of social participation and social capital in shaping health related behaviour. Soc Sci Med . 2001; 52 (3): 441-451 PubMed Abstract | Reference Source Competing Interests: No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Leischik R. Reviewer Report For: L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] . F1000Research 2017, 3 :306 ( https://doi.org/10.5256/f1000research.6279.r7756 ) The direct URL for this report is: https://f1000research.com/articles/3-306/v1#referee-response-7756 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 12 Dec 2014 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 Version 2 (revision) 22 Jun 17 read Version 1 12 Dec 14 read read Roman Leischik , Witten/Herdecke University, Hagen, Germany Majid Ghayour-Mobarhan , Mashhad University of Medical Science, Mashhad, Iran Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2017 Ghayour-Mobarhan M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 03 Jul 2017 | for Version 2 Majid Ghayour-Mobarhan , Cardiovascular Research Center, Mashhad University of Medical Science, Mashhad, Iran 0 Views copyright © 2017 Ghayour-Mobarhan M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The authors have edited the manuscript according to the referee comments. Competing Interests No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Ghayour-Mobarhan M. Peer Review Report For: L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] . F1000Research 2017, 3 :306 ( https://doi.org/10.5256/f1000research.12610.r23982) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/3-306/v2#referee-response-23982 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2015 Ghayour-Mobarhan M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 14 Apr 2015 | for Version 1 Majid Ghayour-Mobarhan , Cardiovascular Research Center, Mashhad University of Medical Science, Mashhad, Iran 0 Views copyright © 2015 Ghayour-Mobarhan M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The title and abstract are appropriate, as are the methods and analysis. The conclusions presented are justified based on the results, and the data provided is sufficient. Please make the following modifications in your article: The statistical correlations between the arginine and the age, BMI and Physical activity should be assessed and reported. On what basis was the arginine dosage selected? The conclusion should be present in a separate section. Competing Interests No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 22 Jun 2017 Mostafa Jafari, Student Research Committee, Arak University of Medical Science, Arak, Iran Dear Referee Your comments on my article with title (L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial) were modified and submitted in new version. but in one comment :(The statistical correlations between the arginine and the age, BMI and Physical activity should be assessed and reported) Because L-arginine levels in serum was not measured during the study, there was no possibility of getting correlation between arginine and age, BMI and PA Thanks View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Ghayour-Mobarhan M. Peer Review Report For: L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] . F1000Research 2017, 3 :306 ( https://doi.org/10.5256/f1000research.6279.r8320) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/3-306/v1#referee-response-8320 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2015 Leischik R. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 03 Mar 2015 | for Version 1 Roman Leischik , Department of Cardiology, Witten/Herdecke University, Hagen, Germany 0 Views copyright © 2015 Leischik R. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The study is well conducted. The data support the conclusions. We don`t know anything about the long-term results. For this issue it is necessary to perform long-term studies. L-Arginine supplement was used in sport, but its positive effects on it are not sure 1 . Plasma nitrite levels were elevated compared to placebo during acute supplement in 5 km runners. We don`t know the long-term effects in patients with diabetes or patients with CAD over the years. But some cited studies in this well conducted study are promising. I think, because of the financial problems we don´t will have a well performed double blinded long-term study in the future. It is therefore quite beneficial to have a well conducted study, especially about possible adverse effects. It is interesting that lowering of blood pressure showed negative effects, but maybe the underlying mechanism in patients with metabolic syndrome might lead to other effects. If it is possible, it would be necessary to get a grant for a long-term study, because the adverse effects are low and possible positive effects might be significant. The problem is that physical activity and healthy life style in general is more important as all supplements. There is a great desire in patients for taking supplements or pills as a solution for their problems and diseases, because then there is no need for an individually effort of the patient itself. I think it is important to mention this. Further studies should be carried out comparing the effects of supplementation of L-Arginine and physical activity in patients. But we have to start somewhere with research and this study is one of the first well conducted and transparent studies. It would be nice if the author can discuss the problem physical activity 2 /life style 3 and supplements in the discussion section. Socioeconomic differences might play a greater role as supplement with L-Arginine 4 . References 1. Sandbakk SB, Sandbakk O, Peacock O, James P, et al.: Effects of acute supplementation of L-arginine and nitrate on endurance and sprint performance in elite athletes. Nitric Oxide . 2014. PubMed Abstract | Publisher Full Text | Reference Source 2. Fiuza-Luces C, Garatachea N, Berger NA, Lucia A: Exercise is the real polypill. Physiology (Bethesda) . 2013; 28 (5): 330-358 PubMed Abstract | Publisher Full Text | Reference Source 3. Edwardson CL, Gorely T, Davies MJ, Gray LJ, et al.: Association of sedentary behaviour with metabolic syndrome: a meta-analysis. PLoS One . 2012; 7 (4). PubMed Abstract | Free Full Text | Publisher Full Text | Reference Source 4. Lindstrom M, Hanson BS, Ostergren PO: Socioeconomic differences in leisure-time physical activity: the role of social participation and social capital in shaping health related behaviour. Soc Sci Med . 2001; 52 (3): 441-451 PubMed Abstract | Reference Source Competing Interests No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Leischik R. Peer Review Report For: L-arginine supplementation and risk factors of cardiovascular diseases in healthy men: a double-blind randomized clinical trial [version 2; peer review: 2 approved] . F1000Research 2017, 3 :306 ( https://doi.org/10.5256/f1000research.6279.r7756) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/3-306/v1#referee-response-7756 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "L-arginine supplementation and risk factors...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/3-306/v2" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/3-306/v2&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/3-306/v2" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Pahlavani N et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/3-306/v2/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/3-306", templates : { twitter : "L-arginine supplementation and risk factors of cardiovascular.... Pahlavani N et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/3-306/v2" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/5877/12610") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "12610"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "8320": 25, "8006": 0, "7110": 0, "7111": 0, "7112": 0, "7113": 0, "7114": 0, "7756": 30, "23982": 15, "7727": 0, "7728": 0, "7729": 0, "7730": 0, "7731": 0, "7732": 0, "7256": 0, "7257": 0, "7258": 0, "7259": 0, "23707": 0, "23708": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "bc8f6c20-dc90-43f7-812f-f52e2de0b14e"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });